Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Conditions: Breast Cancer Interventions: Drug: Tucatinib; Drug: Trastuzumab; Drug: Pertuzumab Sponsors: The Netherlands Cancer Institute; Seagen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
Conditions: Malignant Solid Neoplasm Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Biological: Pertuzumab; Procedure: Radiologic Examination; Biological: Trastuzumab Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
Conditions: Oral Squamous Cell Carcinoma Interventions: Drug: Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy Sponsors: Xuekui Liu Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Conditions: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Interventions: Drug: SHR-A1811; Drug: Trastuzumab Emtansine Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Conditions: Advanced Breast Cancer; Objective Response Rate; Trastuzumab Emtansine Interventions: Drug: Trastuzumab Emtansine (T-DM1) Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Conditions: Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation Interventions: Drug: Pembrolizumab; Drug: Trastuzumab Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
Conditions: Adenocarcinoma; Stomach Neoplasm; Gastroesophageal-junction Cancer; Oligometastatic Disease; Metastatic Cancer; Metastatic Gastric Cancer; Adenocarcinoma of the Stomach; Gastroesophageal Junction Adenocarcinoma; Metastatic Adenocarcinoma Interventions: Radiation: Radiotherapy targeted to the primary lesion; Radiation: Radiotherapy targeted to the metastatic lesions; Biological: Anti-PD-1 monoclonal antibody; Biological: Trastuzumab; Drug: Chemotherapy; Procedure: R0 total/subtotal gastrectomy with D2 lymphadenectomy; Procedure: Metastasectomy; Procedure: Local ablative therapies Sponsors: Fudan University Recru...
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Conditions: GastroEsophageal Cancer; Gastric Cancer Interventions: Drug: Neratinib; Drug: Trastuzumab; Drug: Oxaliplatin; Drug: 5-Fluorouracil + leucovorin; Drug: Pembrolizumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Puma Biotechnology, Inc.; National Comprehensive Cancer Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab ® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Conditions: HER2-positive Breast Cancer Interventions: Drug: HS022; Drug: Trastuzumab; Drug: Vinorelbine Bitartrate Sponsors: Zhejiang Hisun Pharmaceutical Co. Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 30, 2023 Category: Research Source Type: clinical trials
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
Conditions: Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic Interventions: Drug: Sacituzumab Govitecan; Drug: Trastuzumab; Drug: Trastuzumab and Hyaluronidase-oysk Sponsors: Adrienne G. Waks; Gilead Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of NK510 to Treat Gastric Cancer
Conditions: Gastric Cancer Interventions: Drug: NK510; Drug: Tislelizumab ，atezolizumab or Trastuzumab Sponsors: Base Therapeutics (Shanghai) Co., Ltd.; Shanghai 10th People ' s Hospital Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Conditions: Stomach Neoplasm Interventions: Drug: Trastuzumab deruxtecan; Drug: Afatinib Sponsors: Jeeyun Lee Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers
Conditions: Metastatic Cancer; HER2 Gene Mutation Interventions: Drug: Neratinib Maleate Sponsors: Korea University Guro Hospital; Korean Cancer Study Group Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Conditions: Brain Cancer; Glioblastoma; Metastatic Cancer; Leptomeningeal Metastasis; Recurrent Glioblastoma Intervention: Drug: Trastuzumab deruxtecan Sponsors: Memorial Sloan Kettering Cancer Center; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Conditions: Brain Cancer; Glioblastoma; Metastatic Cancer; Leptomeningeal Metastasis; Recurrent Glioblastoma Interventions: Drug: Trastuzumab deruxtecan Sponsors: Memorial Sloan Kettering Cancer Center; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials
